ArticleTherapeutic advances in hematology2025
Effective engraftment via granulocyte transfusion in pre-engraftment febrile neutropenia following allogeneic hematopoietic stem cell transplantation: granulocyte transfusion as bridge therapy.
Article in Therapeutic advances in hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is crucial for treating high-risk hematological cancers. Posttransplant infections are a leading cause of mortality and morbidity, especially before engraftment. This study evaluated the effects of granulocyte transfusion (GT) therapy on neutrophil and platelet (PLT) engraftment in patients with febrile neutropenia during the pre-engraftment phase following allo-HSCT with a control group. Methods: We retrospectively analyzed 56 patients who underwent allo-HSCT from January 2019 to January 2024, dividing them into two groups: those who received GT (GTG) and those who did not (non-GTG). Results: A total of 76 GTs were administered to 28 patients with febrile neutropenia during the pre-engraftment period. The median granulocyte dose was 5.4 × 10 Conclusion: This study is the first to include a control group and demonstrate a statistically significant association between GT therapy in the pre-engraftment period and shortened engraftment times in allo-HSCT recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.